Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Compared with sunitinib alone, nivolumab plus cabozantinib therapy was associated with a 49% decreased risk for progression and 40% decreased risk for death.
Kidney microstructural features appear predictive of progressive CKD and mortality following radical nephrectomy.
Immunotherapy improved median overall survival by 7.5 months regardless of what other treatments patients received.
There is evidence to support the role of metastasectomy in providing patients with mRCC an improvement in certain clinical outcomes.
Investigators highlight the importance of preoperative renal biopsy to rule out an indolent or benign tumor in patients with stage 4 CKD.
A study showed that mortality risk was reduced by 59% for patients who underwent complete metastasectomy compared with those who did not.
Hemodialysis was found to be a poor prognostic factor for patients with RCC.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
Clear cell renal cell carcinoma tumors grow at a faster rate than papillary type 1 tumors, according to a new study.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
An assay that measures tumor-derived cell-free DNA in plasma discriminated between patients with and without renal cell carcinoma with 99% accuracy.
The increase is thought to be related to environmental factors.
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
Combining 2 predictors yielded better results than just using 1.
Patients who have metastatic renal cell carcinoma with sarcomatoid differentiation in the primary tumor have an increased risk for death following cytoreductive nephrectomy, study found.
Upfront cytoreductive nephrectomy for mRCC patients with certain clinical characteristics may enable them to defer systemic therapy for a prolonged interval.
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
Among patients with renal cell carcinoma, those on hemodialysis have a 5 times higher risk of dying from the cancer than those not on dialysis, a study found.